Mayukh Sukhatme has sold ROIV and made no open-market buys since Dec 2025

Mayukh Sukhatme, M.D., is a corporate insider at Roivant Sciences Ltd. and serves as President and Chief Investment Officer( In that role, he is responsible for identifying and diligencing new therapeutic programs, shaping development strategy, and making capital allocation decisions across Roivant’s biopharmaceutical portfolio( He was appointed to Roivant’s Board of Directors in 2023 and has also been listed as a director of Roivant Sciences, Inc.(

Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and Chief Business Officer( Before joining Roivant, he spent 2000 to 2015 as a healthcare-focused analyst and portfolio manager at large institutional investment firms, with a focus on development-stage biotechnology and pharmaceutical companies( He earned his M.D. from Harvard Medical School and B.S. degrees in Biology and Literature from MIT(

Written by Perplexity from public sources.